A to Z / Metabolic / weight loss
Retatrutide
Also known as LY3437943, triple agonist, triple G.
What it is
Retatrutide is an experimental injectable drug being developed for obesity and type 2 diabetes. It is a triple agonist: it acts on three hormone receptors at once (GLP-1, GIP and glucagon), where semaglutide targets one and tirzepatide two.
It has promising phase-2 results and is still in clinical development. It is not approved anywhere in the world, and it cannot be prescribed outside a clinical trial.
It is also the single most-searched compound in this entire book, roughly 2.8 million US searches a month, more than semaglutide and tirzepatide combined. The gap between that interest and its availability shapes much of this entry.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Tirzepatide, Semaglutide, Survodutide, CagriSema
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Retatrutide. It is not medical advice and not a recommendation to use it.